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1. Introduction  
In the industrialized countries, the cardiovascular disease (CVD) is the leading cause of 
mortality and morbidity in women after of 50 years. Genetic, hormonal and metabolic 
influences are involved in gender differences, including the epidemiology, symptoms, 
diagnosis, progression, prognosis and management of these pathologies.  
Recent advances in the field of cardiovascular medicine have not led to significant drops in 
case fatality rates for women, compared to the dramatic reductions achieved for men. Such 
gender-specific difference in cardiovascular disease mortality are probably related to a 
knowledge gap about CVD in women. Thus, much of the evidence supporting 
contemporary recommendations for testing, prevention, and treatment of CVD in women is 
extrapolated from studies conducted predominantly on middle-aged men. For example 
pharmacological therapy is hampered by defective evidence.  
Only recently, significant sex-related differences in prevalence, presentation, management 
and outcomes of CVD, have been evaluated and discovered.  
The ability of knowing and recognizing gender differences in CVD may facilitate a rapid 
identification of cardiac signs and symptoms of warning and may avoid significant delays in 
diagnosis and treatment in women. This compendium will briefly summarize gender-
related differences in several manifestations of CVD, with a special focus also on 
arrhythmias and heart failure.  
2. Risk factors 
Traditionally, guidelines classify women as being at high, intermediate or low risk on risk 
profile, based on Framingham risk scores. Despite major traditional risk factors are the same 
in both sexes, gender-specific differences are noted, and these differences are related to 
different outcome. For this reason, a new approach in evaluation of cardiovascular risk in 
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women considers a multifactorial model that includes a complex interaction between sex 
hormones and traditional risk factors.  
2.1 Traditional risk factors 
There is also substantial gender-related differences in the prevalence and outcome in 
traditional risk factors. For example, overall rates of hypertension and smoking are higher in 
men, but their presence is associated with a worse outcome in women. The prevalence of 
hypertension is lower in pre-menopausal women than men, whereas in post-menopausal 
women it is higher than in men. In fact about 50% of post-menopausal women experience of 
moderate to severe hypertension or take antihypertensive therapy.  
Several studies have clearly demonstrated a strong relationship between level of blood 
pressure and risk for cardiovascular events. In this setting, hypertension is one of the most 
risk factors for stroke, myocardial infarction, heart failure, aortic disease and chronic renal 
failure. Mechanisms responsible for the increase in blood pressure in post-menopausal 
women are complex and multifactorial, including loss of estrogen, oxidative stress, 
endothelial dysfunction, modification in renin-angiotensin system and sympathetic 
activation.  
Hypertension may appears as an isolated disease, more typical of elderly women, or as part 
of the metabolic syndromes (MS), more frequently in early postmenopausal women. MS is a 
constellation of interrelated risk factors that promote the development of CVD. The presence 
of MS worsens the severity of hypertension and reduces the response to treatment. Than, 
MS is considered a unfavourable prognostic factor in hypertension post-menopausal 
women. On the other hand hypertension tends to associate with other metabolic risk factors 
and about one-half patients with essential hypertension are insulin resistant. In addition 
women with MS have chronic subclinical inflammation and systemic endothelial 
dysfunction. Endothelial dysfunction is common after the menopause and its detection may 
precede overt disease such as hypertension and diabetes.  
Data derived from population studies demonstrate that total cholesterol measurements are 
higher in men until the fifth decade of life but, beyond this age, women have greater values. 
Examining the lipoprotein subclassis, women have less LDL particles than men and have 
about two-fold higher concentration of HDL particles then men. Particularly, HDL 
cholesterol inversely correlates with coronary artery disease (CAD) in young men and in 
women of all ages. Women typically experience a relatively mild decline in HDL cholesterol 
at the time of menopause.  
Hypertriglyceridemia is also a more potent independent risk factor for CAD in women as 
compared with men. In fact, in presence of hypertriglyceridemia, the risk of CVD is twice in 
women.  
Another strong risk factors in women is diabetes. Diabetic women have significantly higher 
cardiovascular mortality when compared with diabetic men, because diabetes eliminates the 
‘female advantage’ of a lower CAD prevalence and outcome risk that exists for the female in 
general population. Furthermore diabetes is an independent predictor of ‘atypical’ 
presentation of acute myocardial infarction in women.  
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At the onset of diabetes-related cardiovascular complications, women have higher out-of-
hospital mortality than men, and those who reach hospital are more likely to die from an 
initial cardiac event and are also at high risk of post-event complications.  
2.2 Gender-specific risk factors 
Other factors are unique to the female: menopause, which affects especially if early and 
hypothalamic-hypoestrogenism occurring in fertile women.  
Menopause is a physiological condition associated with endothelial dysfunction, due to lack 
of estrogens. Than, the deficiency of female gonadal hormones may represent a major risk 
factor for menopausal hypertension, due to related modifications of blood vessel structure 
and the elicit response to a vasoactive substances.  
Furthermore, dysfunction of the endotelium causes reduction or abolition of 
vasoprotective factors, inducing a proinflammatory, proliferative and procoagulatory 
milieu. These changes favour the development of cardiovascular risk factors, as 
hypertension.  
Gender-specific opportunities for identifying women’s risk (e.g., prior preeclampsia) also 
deserve further exploration.  
Preeclampsia is a disorder of pregnancy diagnosed by gestational hypertension and 
proteinuria. Abnormal placentation resulting in preeclampsia and intrauterine growth 
restriction is a major cause of both maternal and perinatal morbidity and mortality.  
Prior preeclampsia is associated with increased risk of CVD, including myocardial 
infarction, ischemic heart disease, stroke and endstage renal disease. Particularly, the 
increased risk for future vascular disease is more pronounced in women with early-onset 
preclampsia. Although the symptoms of preeclampsia resolve over a number of weeks after 
delivery, maternal vascular dysfunction may persist for years.   
Endothelial dysfunction, however, is considered a central component of the 
pathophysiology of preeclampsia and known to contribute to the pathogenesis of 
hypertension and cardiovascular sequelae. Several factors contribute to the endothelial 
dysfunction in the post-partum state. Abnormal placenta, for example, release 
antiangiogenic factors, harmful to the vascular endothelium. Often, women with a history of 
peeclampsia or intrauterine growth restriction have high cholesterol levels, high blood 
pressure and insulin resistance.  
Frequently, preeclamptic women are obese, and obesity associated with insulin resistance, 
may reduce endothelial dependent blood flow response.  
Behavioral factors also, such as chronic stress, lack of social support, and family demands, as 
well as biological processes, including genetics, may contribute to the development of CVD 
in this setting.  
Similarly, women with a history of polycystic ovary syndrome have a increased risk of CVD 
and have a greater frequency of multiple risk factors including central obesity, insulin 
resistance, and a greater prevalence of the metabolic syndrome and diabetes.  
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2.3 Inflammatory risk factors 
Beside the traditional and female specific risk factors, novel risk markers such as 
inflammatory markers are being studied.  
Women are at increased risk of inflammatory and autoimmune disease. The risk of 
mortality and morbidity from CVD is very high in autoimmune diseases, as systemic lupus 
erythematosus or rheumatoid arthritis. Various possible mechanisms have been proposed to 
explain the excess rate of cardiovascular mortality in patients with autoimmune disease. 
A combination of traditional (dyslipidemia, hypertension, diabetes, and smoking) and 
nontraditional risk factors, including high inflammation, antiphospholipid antibodies and 
lipid oxidation, contribute to CVD in autoimmune diseases. Inflammation is a key 
component in the development of atherosclerosis in this setting. In fact, inflammation leads 
to the activation of endothelial cells, which, through an increase in the expression of 
leukocyte adhesion molecules, promotes a pro-atherosclerotic environment. Expression of 
proinflammatory cytokines and inflammatory mediators influences all stages of 
atherosclerosis development, from early atheroma formation to thrombus development 
responsible for events such as myocardial infarction. Proinflammatory cytokines may 
promote both traditional (e.g., dyslipidemia, insulin resistance) and nontraditional (e.g., 
oxidative stress) systemic cardiovascular risk factors.  
Than in these patients, is commonly found a presence of endothelial dysfunction, a loss of 
arterial compliance and dysfunction in the microvascolature, resulting in myocardial flow 
heterogeneity.  
Others factors contribute to poor prognosis: undertreatment of cardiovascular comorbidity 
may contribute to increased cardiovascular mortality in these patients. However, some 
drugs, largely used in this setting, may worsen cardiovascular profile: e.g. corticosteroids 
promote hypertension, dyslipidemia, and diabetes. 
Then, novel risk stratification, including inflammatory markers and reproductive hormones, 
is developing to assess global cardiovascular risk in women. 
3. Coronary heart disease 
Coronary heart disease (CHD) is the most common cause of death amongst women, who 
experience more complications after acute myocardial infarction (AMI) than men.  
It has been demonstrated that the epidemiology, the clinical manifestation and the 
progression of CHD are different in both sexes. The women developed CHD about 10-20 
years later than men, in part by the influence of hormones and in part by the genetic sex.  
Particularly, at the time of first experience of AMI, women are more likely to have diabetes 
mellitus or heart failure (HF) than men.  
In addition, the prevalence of obstructive coronary disease is particularly low in 
premenopausal women, whilst increases dramatically for a woman after age 50. 
The most common initial presentation of CHD is a AMI or sudden cardiac death and up to 
half of all women presenting with an acute myocardial infarction report no prior chest pain 
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symptoms. There would appear to be an interaction effect of symptom presentation with 
age, in that older women often present in a similar way to men.  
Several studies have indicated that women have “atypical” symptoms such as back pain, 
dyspnea, indigestion, nausea/vomiting and weakness. Frequently women reported pain in 
the jaw and neck and describe their symptoms as more anguished and frightening 
(emotional component) compared with men. Furthermore, prodromal symptoms are 
described up to 1 month before the onset of AMI such unusual fatigue (70.7%), sleep 
disturbance (47.8%) and shortness of breath (42.1%). The atypical presentation may explain 
the rate of under-diagnosed AMI, the under treatment of acute coronary syndromes and the 
worse outcomes characterized by increased hospital morbidity, higher mortality and fewer 
evidence-based therapies in women.  
In the postmenopausal women, the plaque rupture is the main mechanism of acute coronary 
syndromes like as in the men. The higher mortality noted for younger women when 
compared with age-matched men is due the higher frequency of plaque erosion (Fig. 1). In 
an autopsy series, women also had a greater frequency of distal microvascular embolization 
in the setting of a fatal epicardial thrombosis when compared to men, independently of the 
type of thrombus or presence of necrosis. AMI and sudden death in women can occur also 
in spontaneous coronary artery dissection. This event is more frequent in the peri-partum 
period and can involve all coronary tree, but more frequently affects the left anterior 
descending artery. The dissection can involve every coronary, but in women frequently 
involves the left anterior descending coronary artery, whereas in man the right coronary 
artery is more frequently involved.  
Many as 50% of patients undergoing coronary angiography for typical or atypical chest pain 
do not have obstructive CAD. An alternative mechanism of pain in women may be a 
coronary microvascular dysfunction, known as syndrome X. Most of these patients have an 
‘abnormal’ exercise stress test, myocardial perfusion defects on gated Single-photon 
emission computed tomography or stress-induced wall motion abnormalities on 
echocardiography, but normal coronary angiography.   
However, differentiation between these mechanisms of chest pain is important, because 
‘noncardiac’ chest pain is not associated with cardiovascular sequelae and may require 
further medical evaluation and treatment. By contrast, syndrome X, which is thought to be 
caused by microvascular dysfunction, is associated with inducible metabolic ischaemia and 
can be treated by improving microvascular vasomotor tone with oral L-arginine, a precursor 
to vascular nitric oxide, and oestrogen.  
Despite the absence of CAD and low risk for adverse cardiac events, a majority of those 
patients continue to have symptoms that contribute to a poor quality of life and 
consumption of large amounts of health care resources because of repeated evaluations and 
hospitalizations. Recently, Han et al. studied patients with obstructive CAD who underwent 
simultaneous intravascular ultrasound and coronary reactivity assessment and 
demonstrated that men have a greater atheroma burden and more diffuse epicardial 
endothelial dysfunction while women have more disease of the microcirculation. The 
coronary micro-vascular dysfunction, the smaller coronary artery lumens, the less collateral 
circulation than men and more prominent positive remodeling support the higher rate of 
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angina, and acute coronary syndromes in the absence of obstructive CAD particularly 
during exertion or stress. 
 
SCD, sudden cardiac death; Th, thrombus 
Fig. 1. Gender differences in plaque morphologic features in an autoptic series of patients 
who died for sudden cardiac death, modified from reference 13. 
4. Heart failure  
The lifetime risk of developing HF is about 20% for both men and women. There are 
differences between men and women in clinical presentation, aetiology, treatment and 
outcome in HF, and these differences lead to different outcome.  
The women are older than men and present more frequent hypertension and diabetes.  
Diabetes mellitus is one of the strongest additional risk factors for the development of HF in 
women with CAD.  
The systolic function is usually better preserved and the prevalence of ischemic etiology is 
lower respect to hypertension and valvular diseases. Another cause of HF includes cardiac 
toxicity from chemotherapeutic agents used to treat breast malignancy. 
Mullens et al. show that the survival rate in women with non-ischemic cardiomyopathy was 
better than men, irrespective of baseline characteristics, while there was no advantage in 
presence of ischemic cause. The reason of different outcome remains unclear but might in 
part be related to sex differences in etiology.  
The diagnosis of HF is a clinical diagnosis based on a constellation of symptoms and signs. 
Women with impaired systolic left ventricular function are more likely than men to have 
dependent edema, jugular venous distension, and an S3 gallop.  
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Furthermore, normal brain natriuretic peptide value, a biomarker used to identify patients 
with symptoms of HF, are higher in women versus men.  
Current guidelines for HF therapy also are not sex specific due to under-representation of 
women and lack of sex-specific, prospective, randomized clinical trials. Indeed, women 
receive less life-prolonging treatment (ACE-I, beta-blockers and spironolactone) than men, 
in the presence of normal left ventricular function, while there no difference if etiology of 
HF is CAD.  
Cardiac resynchronization therapy, an important therapy for HF, is beneficial for both 
women and men. Data suggest CRT is preferable to medical therapy alone in women for the 
combined end point of total mortality and hospital stay for major cardiovascular events.  
A peculiar type of left ventricular dysfunction and HF typical in women is Takotsubo 
cardiomyopathy. This disease is typically observed in post-menopausal women and the 
highest frequency of occurrence is between the seventh and eighth decade of life.  
The reason for the much more common occurrence in postmenopausal women is unclear.  
It is characterized by a left ventricular dysfunction, electrocardiographic changes like an 
acute myocardial infarction and release of cardiac biomarkers, in the absence of obstructive 
coronary disease. The emotionally or physical stress are usually the triggers. The 
catecholamine-mediated cardio-toxicity, multi-vessels coronary vasospasm and 
abnormalities in coronary micro-vascular function have been postulated as 
pathophysiologic mechanisms.  
The left ventricular dysfunction is reversible within weeks, despite a dramatic clinical 
presentation (similar to acute myocardial infarction but in the absence of obstructive 
coronary disease) and substantial risk of complications in the acute setting. 
Another cause of left ventricular dysfunction and HF typical in women is peripartum 
cardiomyopathy (PPCM). This disease develops in the last month of pregnancy or within 5 
months post-partum with no pre-existing cardiac disease or identifiable cause. The 
incidence is very low (<1%) and varies on the basis of the population studied. Risk factors 
include advanced maternal age, African descent, twin pregnancy, usage of tocolytics, and 
poverty.  
The etiology remains unknown, but potential causes include abnormal immune response to 
pregnancy, increased myocyte apoptosis, genetic predisposition. Only 20% may worsen up 
to the death or transplantation, while one-half of PPCM patients recover normal systolic 
function within 6 months.  
5. Arrhythmias  
It is been demonstrated that women had a higher resting heart rate than did men (3 to 5 
beats faster for minute). These finding may be explained by differences in exercise tolerance, 
autonomic modulation and intrinsic properties of the sinus node, influencing in part by 
hormonal influences. Burke et al. reported an higher average heart rate during the follicular 
or luteal phases of the menstrual cycle, although the response to double autonomic blockade 
was identical regardless of phase.  
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Several authors demonstrated differences in QT interval between men and women. Women 
have a longer corrected QT interval and the difference becomes more pronounced at lower 
heart rates. Rautaharju et al. reported that this difference was due to a drop in the corrected QT 
that occurred in males after puberty (when androgen levels are highest). Then, the interval in 
men gradually increased with age until 50 years, at which point it paralleled that of women. 
The actions of hormonal influences in QT differences was confirmed in families with 
genotipically characterized long QT syndrome. In addition, the torsades de pointes correlated 
to both congenital and acquired long QT Syndrome was more frequent in women.  
There are many differences in incidence, prevalence, presentation and clinical course of 
many arrhythmias. Inappropriate sinus tachycardia is more common in women. Rodigruez 
et al. reported in patients undergoing invasive electrophysiologic testing for various 
tachycardias that the atrio-ventricular node reentrant tachycardia (AVNRT) was twice times 
more common in women, whereas atrial tachycardia affected both sexes equally. In 
addition, the atrio-ventricular reentrant (circus-movement) tachycardia (AVRT), atrial 
fibrillation (AF), and ventricular fibrillation (VF) occurred more often in men. These trends 
for supra-ventricular tachycardias (SVTs), AF, VF, were confirmed in the Framingham 
cohort. Myerburg and associates found that the inducing SVT during electrophysiologic 
testing was greatest at the onset of menses or during the premenstrual phase. Rossano et al. 
confirmed that the SVT prone state is hindered by estrogen and facilitated by progesterone.  
The SVTs new- onset or exacerbation are most common arrhythmia during pregnancy and 
the postpartum period in absence o f structural heart disease. The mechanisms for increase 
in this situation may be related to progesteronerich gravid state, increased intravascular 
volume and autonomic tone.  
The Atrial Fibrillation (AF) is the most prevalent in men, although its incidence increases 
with age both in men and women. Women with AF are more symptomatic, older and have 
lower quality of life and more co-morbidities than men. Also they present more likely a 
higher heart rate, longer episodes and increase incidence of embolic strokes compared to 
men. Data from the Euro Heart Survey on Atrial Fibrillation demonstrated that women are 
usually treated less aggressively, with fewer cardioversions and catheter ablations. In this 
study, albeit both genders received anticoagulation therapy, women experienced a 
significantly higher rate of stroke and major bleeding events.  
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